Who
Andrea Heslin Smiley
Director
Company insider
Files Form 4 as: Director, AtaiBeckley; Director, ATAI Life Sciences; Director, Rockwell Medical; Director, Assertio Holdings; Director, Zyla Life Sciences.
In numbers
- Trades disclosed
- 43
- Buys
- 1
- Sells
- 0
- Bought
- $70K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 1 May 2017
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —4,666 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —4,666 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 20 May 2025filed 21 May 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —36,111 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —24,715 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.